Cagrilintide
AM833 · long-acting amylin analog
Long-acting amylin analog; often paired with GLP-1s in trials.
An acylated amylin analog that slows gastric emptying and increases satiety. CagriSema (cagrilintide + semaglutide) is an investigational combo.
Usual range
0.3–2.4 mg
Schedule
Once weekly
Half-life
~7 days
How it is used
Long-acting amylin analog; often paired with GLP-1s in trials.
Subcutaneous
Weekly. If stacked with a GLP-1, same day or as a clinician directs.
Trial-length; always titrate.
How to mix this vial
Typical vial 5 mg · 2 mL BAC
5 mg + 2 mL → 2.5 mg/mL. 0.6 mg ≈ 24 units. Confirm labeled mass.
Fridge.
Side effects
- Nausea
- Early fullness
- Constipation
Who should skip this
- Pregnancy
- Significant gastroparesis
Nutrition note
Even smaller meals than GLP-1 alone. Chew well; stop early.
Stacks
Often paired with
Not approved as monotherapy in most markets.
Peptipedia is an educational calculator, not medical advice. Many catalog entries are unapproved for human use. Approved molecules have labels that outrank this app. Do not use this to self-prescribe. Consult a licensed clinician. Not for anyone under 18, pregnant, or being treated for cancer.